TrianglePUBLICATIONS · 29860922
Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3.
Open original source → · Download preserved record
Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.
- Journal
- J Clin Oncol
- Publication date
- 2018 Aug 20
- First author
- Slamon DJ
Publication notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
Authors and identifiers
- name
- Slamon DJ
- type
- Author
- name
- Neven P
- type
- Author
- name
- Chia S
- type
- Author
- name
- Fasching PA
- type
- Author
- name
- De Laurentiis M
- type
- Author
- name
- Im SA
- type
- Author
- name
- Petrakova K
- type
- Author
- name
- Bianchi GV
- type
- Author
- name
- Esteva FJ
- type
- Author
- name
- Martín M
- type
- Author
- name
- Nusch A
- type
- Author
- name
- Sonke GS
- type
- Author
Complete bibliographic record and source provenance
- authors
- name
- Slamon DJ
- type
- Author
- name
- Neven P
- type
- Author
- name
- Chia S
- type
- Author
- name
- Fasching PA
- type
- Author
- name
- De Laurentiis M
- type
- Author
- name
- Im SA
- type
- Author
- name
- Petrakova K
- type
- Author
- name
- Bianchi GV
- type
- Author
- name
- Esteva FJ
- type
- Author
- name
- Martín M
- type
- Author
- name
- Nusch A
- type
- Author
- name
- Sonke GS
- type
- Author
- bibliography ids
- nci-bib-608240b12c4427e4f9e94001
- book metadata
- content sha256
- 36ef20e1a0d243f9a08a8c298e3a75e2bdada9726fee0a56518b8fa5892a3b14
- document type
- citation
- dois
- 10.1200/JCO.2018.78.9909
- electronic publication date
- display
- 2018 Jun 3
- precision
- day
- year
- 2018
- evidence scope
- bibliographic_metadata_only
- id
- pubmed:29860922
- immutable id
- pubmed:29860922@36ef20e1a0d243f9a08a8c298e3a75e2bdada9726fee0a56518b8fa5892a3b14
- journal
- abbreviation
- J Clin Oncol
- issn electronic
- 1527-7755
- issn print
- 0732-183X
- issue
- 24
- name
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- nlm unique id
- 8309333
- pages
- 2465-2472
- volume
- 36
- languages
- eng
- notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
- outcomes validated
- false
- pmid
- 29860922
- provenance
- batch id
- c4c0356d060413f719c2
- provider
- NCBI PubMed ESummary
- record sha256
- abd3052db1e89b27bd02f851ed91381057ddc0831782b8e8b950fc0a8ace5473
- response sha256
- adeb6beaad718f060a94981fd9e96a2eaddc4f781839549cb3e53cba822117c0
- retrieved at
- 2026-09-09T23:47:33.674758+00:00
- publication date
- display
- 2018 Aug 20
- precision
- day
- year
- 2018
- publication types
- Clinical Trial, Phase III
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
- record status
- PubMed - indexed for MEDLINE
- schema version
- 1.0
- title
- Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3.
Preserved source evidence · Not medical advice